Canada Life’s Sage Therapeutics SAGE Stock Holding History

Canada Life’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,789	Closed	-$26K	–	2017
2024 Q4	$26K	Hold	4,789	–	–	﹤0.01%	1934
2024 Q3	$35K	Hold	4,789	–	–	﹤0.01%	1979
2024 Q2	$52K	Hold	4,789	–	–	﹤0.01%	1964
2024 Q1	$90K	Hold	4,789	–	–	﹤0.01%	1953
2023 Q4	$103K	Hold	4,789	–	–	﹤0.01%	1943
2023 Q3	$99K	Buy	4,789 +2,800	+141%	+$80.9K	﹤0.01%	1965
2023 Q2	$94K	Sell	1,989 -516	-21%	-$25.7K	﹤0.01%	1934
2023 Q1	$105K	Hold	2,505	–	–	﹤0.01%	1976
2022 Q4	$96K	Hold	2,505	–	–	﹤0.01%	1993
2022 Q3	$98K	Hold	2,505	–	–	﹤0.01%	1990
2022 Q2	$81K	Hold	2,505	–	–	﹤0.01%	1954
2022 Q1	$88K	Sell	2,505 -492	-16%	-$18.5K	﹤0.01%	2030
2021 Q4	$127K	Hold	2,997	–	–	﹤0.01%	1958
2021 Q3	$134K	Hold	2,997	–	–	﹤0.01%	1994
2021 Q2	$170K	Sell	2,997 -456	-13%	-$32.2K	﹤0.01%	1963
2021 Q1	$257K	Hold	3,453	–	–	﹤0.01%	1886
2020 Q4	$298K	Hold	3,453	–	–	﹤0.01%	1876
2020 Q3	$211K	Hold	3,453	–	–	﹤0.01%	1891
2020 Q2	$143K	Hold	3,453	–	–	﹤0.01%	1974
2020 Q1	$100K	Hold	3,453	–	–	﹤0.01%	1976
2019 Q4	$247K	Buy	+3,453	New	+$425K	﹤0.01%	1877
2019 Q3	–	Sell	-6,156	Closed	-$1.13M	–	2050
2019 Q2	$1.13M	Sell	6,156 -95	-2%	-$16.2K	﹤0.01%	1482
2019 Q1	$991K	Buy	6,251 +574	+10%	+$83.1K	﹤0.01%	1385
2018 Q4	$525K	Buy	5,677 +491	+9%	+$56.2K	﹤0.01%	1659
2018 Q3	$733K	Hold	5,186	–	–	﹤0.01%	1628
2018 Q2	$812K	Hold	5,186	–	–	﹤0.01%	1607
2018 Q1	$837K	Buy	5,186 +1,024	+25%	+$174K	﹤0.01%	1570
2017 Q4	$684K	Hold	4,162	–	–	﹤0.01%	1638
2017 Q3	$261K	Hold	4,162	–	–	﹤0.01%	1884
2017 Q2	$331K	Hold	4,162	–	–	﹤0.01%	1797
2017 Q1	$295K	Hold	4,162	–	–	﹤0.01%	1824
2016 Q4	$213K	Hold	4,162	–	–	﹤0.01%	1900
2016 Q3	$191K	Hold	4,162	–	–	﹤0.01%	1917
2016 Q2	$125K	Hold	4,162	–	–	﹤0.01%	2023
2016 Q1	$133K	Buy	4,162 +3,267	+365%	+$115K	﹤0.01%	1583
2015 Q4	$52K	Hold	895	–	–	﹤0.01%	2125
2015 Q3	$38K	Hold	895	–	–	﹤0.01%	2191
2015 Q2	$65K	Buy	+895	New	+$57.5K	﹤0.01%	2093

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Canada Life's SAGE Position: Q1 2025 in Review

Canada Life sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 4,789 shares — an estimated $26K sold.

Canada Life first reported a position in SAGE in Q2 2015 and held it in 38 quarters. The position peaked at $1.13M in Q2 2019. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Canada Life reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
Canada Life sold 4,789 Sage Therapeutics shares in Q1 2025, an estimated $26K.
Canada Life first reported a position in Sage Therapeutics in Q2 2015 and held it in 38 quarters.
Canada Life's Sage Therapeutics position peaked at $1.13M in Q2 2019.
198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Canada Life's 13F filing for Q1 2025, filed 15 May 2025.